PTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Misses Estimates By $0.76 EPS

PTC Therapeutics (NASDAQ:PTCT) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76), FiscalAI reports. The company had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. PTC Therapeutics’s revenue was up 69.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.20 EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Stock Up 2.3%

PTC Therapeutics stock traded up $1.44 during trading hours on Thursday, reaching $64.46. 1,524,172 shares of the company’s stock were exchanged, compared to its average volume of 996,871. The firm has a market capitalization of $5.38 billion, a PE ratio of -111.14, a PEG ratio of 1.90 and a beta of 0.49. The firm’s 50 day simple moving average is $65.57 and its 200 day simple moving average is $70.87. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PTCT shares. Truist Financial initiated coverage on shares of PTC Therapeutics in a report on Friday, October 16th. They set a “hold” rating and a $62.00 target price on the stock. Leerink Partners began coverage on shares of PTC Therapeutics in a research note on Monday, September 14th. They set an “outperform” rating and a $98.00 price target for the company. UBS Group initiated coverage on shares of PTC Therapeutics in a report on Thursday, October 15th. They set a “buy” rating and a $90.00 price target on the stock. Zacks Research cut shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, Cantor Fitzgerald boosted their price objective on shares of PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.93.

Insider Buying and Selling

In other PTC Therapeutics news, Director Michael Schmertzler sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total value of $149,025.00. Following the transaction, the director directly owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of the stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total value of $781,920.00. Following the transaction, the director owned 22,500 shares in the company, valued at $1,466,100. The trade was a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,370 shares of company stock valued at $5,322,261 over the last 90 days. Company insiders own 5.30% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.